{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:23:14Z","timestamp":1790619794807,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"44","license":[{"start":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T00:00:00Z","timestamp":1327276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T00:00:00Z","timestamp":1327276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2012,11,1]]},"DOI":"10.1038\/onc.2011.614","type":"journal-article","created":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T16:23:27Z","timestamp":1327335807000},"page":"4677-4688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP"],"prefix":"10.1038","volume":"31","author":[{"given":"A","family":"Bangert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Cristofanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B A","family":"Abhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kolodziej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"H\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S H K","family":"Vellanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-M","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Fulda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,23]]},"reference":[{"key":"BFonc2011614_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3322\/caac.20069","volume":"60","author":"EG Van Meir","year":"2010","unstructured":"Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ . Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60: 166\u2013193.","journal-title":"CA Cancer J Clin"},{"key":"BFonc2011614_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459\u2013466.","journal-title":"Lancet Oncol"},{"key":"BFonc2011614_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/35037710","volume":"407","author":"MO Hengartner","year":"2000","unstructured":"Hengartner MO . The biochemistry of apoptosis. Nature 2000; 407: 770\u2013776.","journal-title":"Nature"},{"key":"BFonc2011614_CR4","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1038\/onc.2010.221","volume":"29","author":"F Gonzalvez","year":"2010","unstructured":"Gonzalvez F, Ashkenazi A . New insights into apoptosis signaling by Apo2L\/TRAIL. Oncogene 2010; 29: 4752\u20134765.","journal-title":"Oncogene"},{"key":"BFonc2011614_CR5","first-page":"123","volume":"1805","author":"B Pennarun","year":"2010","unstructured":"Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S . Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta 2010; 1805: 123\u2013140.","journal-title":"Biochim Biophys Acta"},{"key":"BFonc2011614_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer G, Galluzzi L, Brenner C . Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87: 99\u2013163.","journal-title":"Physiol Rev"},{"key":"BFonc2011614_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","volume":"94","author":"H Li","year":"1998","unstructured":"Li H, Zhu H, Xu CJ, Yuan J . Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491\u2013501.","journal-title":"Cell"},{"key":"BFonc2011614_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.coi.2007.05.004","volume":"19","author":"JM Adams","year":"2007","unstructured":"Adams JM, Cory S . Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488\u2013496.","journal-title":"Curr Opin Immunol"},{"key":"BFonc2011614_CR9","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.1038\/onc.2008.302","volume":"27","author":"EC LaCasse","year":"2008","unstructured":"LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG . IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252\u20136275.","journal-title":"Oncogene"},{"key":"BFonc2011614_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/9783527619665.ch4","volume-title":"Apoptosis and Cancer Therapy","author":"O Micheau","year":"2006","unstructured":"Micheau O . Cellular FLICE-inhibitory protein: an update. In: Debatin KM, Fulda S (eds). Apoptosis and Cancer Therapy. Wiley-VCH: Heidelberg, 2006, pp 120\u2013157."},{"key":"BFonc2011614_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A . Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001\u20131012.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2011614_CR12","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1365-2990.2010.01069.x","volume":"36","author":"JM Kuijlen","year":"2010","unstructured":"Kuijlen JM, Bremer E, Mooij JJ, den Dunnen WF, Helfrich W . Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol 2010; 36: 168\u2013182.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFonc2011614_CR13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/156800908783769355","volume":"8","author":"S Fulda","year":"2008","unstructured":"Fulda S . Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008; 8: 132\u2013140.","journal-title":"Curr Cancer Drug Targets"},{"key":"BFonc2011614_CR14","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1158\/1535-7163.MCT-08-0860","volume":"8","author":"L Ellis","year":"2009","unstructured":"Ellis L, Atadja PW, Johnstone RW . Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409\u20131420.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011614_CR15","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769\u2013784.","journal-title":"Nat Rev Drug Discov"},{"key":"BFonc2011614_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38\u201351.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2011614_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/emboj\/19.4.662","volume":"19","author":"MA Martinez-Balbas","year":"2000","unstructured":"Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T . Regulation of E2F1 activity by acetylation. EMBO J 2000; 19: 662\u2013671.","journal-title":"EMBO J"},{"key":"BFonc2011614_CR18","doi-asserted-by":"publisher","first-page":"34725","DOI":"10.1074\/jbc.R600017200","volume":"281","author":"J Vervoorts","year":"2006","unstructured":"Vervoorts J, Luscher-Firzlaff J, Luscher B . The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006; 281: 34725\u201334729.","journal-title":"J Biol Chem"},{"key":"BFonc2011614_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1677\/ERC-08-0153","volume":"15","author":"C Weidinger","year":"2008","unstructured":"Weidinger C, Krause K, Klagge A, Karger S, Fuhrer D . Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer 2008; 15: 917\u2013929.","journal-title":"Endocr Relat Cancer"},{"key":"BFonc2011614_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","volume":"280","author":"AJ Frew","year":"2009","unstructured":"Frew AJ, Johnstone RW, Bolden JE . Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009; 280: 125\u2013133.","journal-title":"Cancer Lett"},{"key":"BFonc2011614_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0960-9822(00)00512-1","volume":"10","author":"T Kataoka","year":"2000","unstructured":"Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000; 10: 640\u2013648.","journal-title":"Curr Biol"},{"key":"BFonc2011614_CR22","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1128\/MCB.21.16.5299-5305.2001","volume":"21","author":"O Micheau","year":"2001","unstructured":"Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J . NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001; 21: 5299\u20135305.","journal-title":"Mol Cell Biol"},{"key":"BFonc2011614_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/cdd.2009.176","volume":"17","author":"T Sanchez-Perez","year":"2010","unstructured":"Sanchez-Perez T, Ortiz-Ferron G, Lopez-Rivas A . Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010; 17: 883\u2013894.","journal-title":"Cell Death Differ"},{"key":"BFonc2011614_CR24","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.1128\/MCB.24.19.8541-8555.2004","volume":"24","author":"MS Ricci","year":"2004","unstructured":"Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004; 24: 8541\u20138555.","journal-title":"Mol Cell Biol"},{"key":"BFonc2011614_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1074\/jbc.M304736200","volume":"279","author":"C Skurk","year":"2004","unstructured":"Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004; 279: 1513\u20131525.","journal-title":"J Biol Chem"},{"key":"BFonc2011614_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/sj.cdd.4401739","volume":"13","author":"C Salon","year":"2006","unstructured":"Salon C, Eymin B, Micheau O, Chaperot L, Plumas J, Brambilla C et al. E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). Cell Death Differ 2006; 13: 260\u2013272.","journal-title":"Cell Death Differ"},{"key":"BFonc2011614_CR27","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1038\/onc.2009.161","volume":"28","author":"S Hacker","year":"2009","unstructured":"Hacker S, Dittrich A, Mohr A, Schweitzer T, Rutkowski S, Krauss J et al. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene 2009; 28: 3097\u20133110.","journal-title":"Oncogene"},{"key":"BFonc2011614_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1067\/msy.2001.115897","volume":"130","author":"A Hernandez","year":"2001","unstructured":"Hernandez A, Thomas R, Smith F, Sandberg J, Kim S, Chung DH et al. Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis. Surgery 2001; 130: 265\u2013272.","journal-title":"Surgery"},{"key":"BFonc2011614_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/blood-2002-12-3794","volume":"102","author":"JL Aron","year":"2003","unstructured":"Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102: 652\u2013658.","journal-title":"Blood"},{"key":"BFonc2011614_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.cdd.4401507","volume":"12","author":"K Watanabe","year":"2005","unstructured":"Watanabe K, Okamoto K, Yonehara S . Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ 2005; 12: 10\u201318.","journal-title":"Cell Death Differ"},{"key":"BFonc2011614_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.21054","volume":"43","author":"A Pathil","year":"2006","unstructured":"Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006; 43: 425\u2013434.","journal-title":"Hepatology"},{"key":"BFonc2011614_CR32","first-page":"6318","volume":"60","author":"KO Mitchell","year":"2000","unstructured":"Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 2000; 60: 6318\u20136325.","journal-title":"Cancer Res"},{"key":"BFonc2011614_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1535-6108(04)00113-8","volume":"5","author":"Y Wang","year":"2004","unstructured":"Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC . Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5: 501\u2013512.","journal-title":"Cancer Cell"},{"key":"BFonc2011614_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/sj.emboj.7601551","volume":"26","author":"AI Nieminen","year":"2007","unstructured":"Nieminen AI, Partanen JI, Hau A, Klefstrom J . c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J 2007; 26: 1055\u20131067.","journal-title":"EMBO J"},{"key":"BFonc2011614_CR35","doi-asserted-by":"publisher","first-page":"6643","DOI":"10.1158\/0008-5472.CAN-08-0850","volume":"68","author":"S Kotliarova","year":"2008","unstructured":"Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res 2008; 68: 6643\u20136651.","journal-title":"Cancer Res"},{"key":"BFonc2011614_CR36","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-03-2629","volume":"64","author":"F Guo","year":"2004","unstructured":"Guo F, Sigua C, Tao J, Bali P, George P, Li Y et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L\/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004; 64: 2580\u20132589.","journal-title":"Cancer Res"},{"key":"BFonc2011614_CR37","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1038\/sj.onc.1208585","volume":"24","author":"TR Singh","year":"2005","unstructured":"Singh TR, Shankar S, Srivastava RK . HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005; 24: 4609\u20134623.","journal-title":"Oncogene"},{"key":"BFonc2011614_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11060-008-9788-x","volume":"93","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S et al. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009; 93: 303\u2013318.","journal-title":"J Neurooncol"},{"key":"BFonc2011614_CR39","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.ejca.2009.06.024","volume":"45","author":"D Carlisi","year":"2009","unstructured":"Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009; 45: 2425\u20132438.","journal-title":"Eur J Cancer"},{"key":"BFonc2011614_CR40","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1158\/1535-7163.MCT-09-0451","volume":"8","author":"S Inoue","year":"2009","unstructured":"Inoue S, Harper N, Walewska R, Dyer MJ, Cohen GM . Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. Mol Cancer Ther 2009; 8: 3088\u20133097.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011614_CR41","doi-asserted-by":"publisher","first-page":"6877","DOI":"10.1038\/sj.onc.1208851","volume":"24","author":"EH Kim","year":"2005","unstructured":"Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS, Choi KS . Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene 2005; 24: 6877\u20136889.","journal-title":"Oncogene"},{"key":"BFonc2011614_CR42","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/stem.89","volume":"27","author":"P Sun","year":"2009","unstructured":"Sun P, Xia S, Lal B, Eberhart CG, Quinones-Hinojosa A, Maciaczyk J et al. DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. Stem Cells 2009; 27: 1473\u20131486.","journal-title":"Stem Cells"},{"key":"BFonc2011614_CR43","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1535-7163.MCT-05-0533","volume":"5","author":"IY Eyupoglu","year":"2006","unstructured":"Eyupoglu IY, Hahnen E, Trankle C, Savaskan NE, Siebzehnrubl FA, Buslei R et al. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 2006; 5: 1248\u20131255.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2011614_CR44","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1073\/pnas.0510341103","volume":"103","author":"MV Simonini","year":"2006","unstructured":"Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006; 103: 1587\u20131592.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2011614_CR45","doi-asserted-by":"publisher","first-page":"6271","DOI":"10.1158\/0008-5472.CAN-07-6769","volume":"68","author":"D Opel","year":"2008","unstructured":"Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S . Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008; 68: 6271\u20136280.","journal-title":"Cancer Res"},{"key":"BFonc2011614_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.2787530","volume":"245","author":"BC Trauth","year":"1989","unstructured":"Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301\u2013305.","journal-title":"Science"},{"key":"BFonc2011614_CR47","first-page":"3823","volume":"57","author":"S Fulda","year":"1997","unstructured":"Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM . The CD95 (APO-1\/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823\u20133829.","journal-title":"Cancer Res"},{"key":"BFonc2011614_CR48","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1111\/j.1582-4934.2009.00888.x","volume":"13","author":"S Karl","year":"2009","unstructured":"Karl S, Pritschow Y, Volcic M, Hacker S, Baumann B, Wiesmuller L et al. Identification of a novel pro-apopotic function of NF-kappaB in the DNA damage response. J Cell Mol Med 2009; 13: 4239\u20134256.","journal-title":"J Cell Mol Med"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2011614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011614","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2011614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:42:38Z","timestamp":1647888158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2011614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,23]]},"references-count":48,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2012,11,1]]}},"alternative-id":["BFonc2011614"],"URL":"https:\/\/doi.org\/10.1038\/onc.2011.614","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,23]]},"assertion":[{"value":"16 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}